Document is current
Any future updates will be listed below
-
Authors
Hall, Nolwenn
Allavena, Clotilde
Katlama, Christine
Jobert, Alexandra
Molina, Jean-Michel
Cua, Eric
Bani-Sadr, Firouzé
Hocqueloux, Laurent
Duvivier, Claudine
Merrien, Dominique
Hikombo, Hitoto
André-Garnier, Elisabeth
Gaultier, Aurélie
Raffi, François
,
Bollengier, Olivier
Guimard, Thomas
Leautez, Sophie
Blanchi, Sophie
Becker, Agathe
Cotte, Laurent
Ferry, Tristan
Perpoint, Thomas
Trabaud, Marie-Anne
Biron, Laetitia
Ferré, Virginie
Flet, Laurent
Reliquet, Véronique
Rodalec, Audrey
Volteau, Christèle
Breaud, Sophie
Puglièse, Pascal
Rosenthal, Eric
De Dieuleveult, Barbara
Prazuck, Thierry
Bachelard, Antoine
Legac, Sylvie
Yazdanpanah, Yazdan
Ghosn, Jade
Kalambay, Myriam
Slama, Laurence
Viard, Jean-Paul
Lourenco, Jérémy
Ktorza, Nadine
Palich, Romain
Schneider, Luminita
Aslan, Alexandre
Tateo, Mariagrazia
Zeggagh, Jeremy
Brodard, Véronique
Hentzien, Maxime
Kmiec, Isabelle
N’Guyen, Yohan
Ajana, Faïza
Bocket, Laurence
Huleux, Thomas
Meybeck, Agnes
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03195452 at ClinicalTrials.govDocuments that mention this clinical trial
Raltegravir 1200 mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial
https://doi.org/10.1186/s12981-022-00428-5
-
Funding
Funding for this research was provided by:
Merck Sharp and Dohme
- License Information
-
More Information
Article History
Received: 18 August 2021
Accepted: 4 January 2022
First Online: 15 January 2022
Declarations
:
: The protocol was approved by the Ethics Committee of Est III (17.04.06), and authorized by the French National Agency for the Safety of Medicines (ANSM 170133A-41). All participants gave written informed consent.
: Not applicable.
: All authors declare that they have no competing interests in relation to this work.
